Last update:
   03-Jul-2023
 

Arch Hellen Med, 40(4), July-August 2023, 467-471

BRIEF REVIEW

Imeglimin: The first of a new class of oral agents for the treatment of type 2 diabetes mellitus

Α.Κ. Papazafiropoulou,1 K. Aloumanis,2 N. Papanas3
1First Department of Internal Medicine and Diabetes Center, "Tzaneio" General Hospital of Pireus, Pireus,
2Endocrinologist, Heraklion, Attica,
3Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece

Imeglimin is the first of "glimins": A new class of oral agents developed for the treatment of type 2 diabetes mellitus (T2DM). Its mechanism of action involves: (a) amplification of glucose-stimulated insulin secretion and preservation of β-cell mass; (b) enhanced insulin action, including inhibition of hepatic glucose output and improved insulin signaling in both liver and skeletal muscle. Clinical studies of imeglimin in humans have shown decreased fasting plasma glucose and hemoglobin A1c. The efficacy of imeglimin was comparable with that of metformin and sitagliptin and was further increased when used in combination with either agent. Imeglimin appears to be a promising antidiabetic agent both as an adjunctive therapy and as monotherapy for T2DM.

Key words: Efficacy, Glimins, Imeglimin, Safety, Type 2 diabetes.

© Archives of Hellenic Medicine